BioCentury | Jun 26, 2020
Distillery Therapeutics

FMR1 peptide therapy for Fragile X syndrome

DISEASE CATEGORY: Neurology INDICATION: Fragile X syndrome An FMR1-based peptide therapy could treat Fragile X syndrome. The therapy comprises a FMR1 N-terminal fragment -- the first 297 residues -- conjugated to a cell-penetrating peptide derived...
BC Innovations | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
BC Innovations | May 20, 2019
Distillery Therapeutics

Brain-penetrating SELP-based peptide for stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest a brain-penetrating SELP-based fusion peptide could help treat stroke. The fusion consists of six amino acids from the C-terminus of SELP, which transports the ferroptosis inhibitor selenium,...
BC Innovations | Jul 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Cell culture and mouse studies suggest virus-targeted delivery of defective versions of viral RNA polymerase subunits PA, PB1 and PB2 genes could help prevent or treat influenza A infection. In canine and...
BC Extra | Oct 20, 2017
Preclinical News

Inhibition of HIV tat could allow patients to halt ART

A paper published in Cell Reports builds on evidence that suggests inhibiting HIV tat protein (HIV tat) could treat HIV by blocking viral transcription and rebound from latent viral reservoirs. In 2015, a team from...
BC Innovations | Jul 27, 2017
Translation in Brief

Cycling across the membrane

In a Nature Chemistry study, a German team has shown that nanobodies coupled to cyclic peptides rich in arginine can target intracellular proteins with antibody-like precision and even deliver extracellular proteins to the cytosol. Delivering...
BC Innovations | Jun 20, 2017
Distillery Therapeutics


INDICATION: Stroke In vitro and mouse studies suggest a peptide inhibitor of the KCNB1 - STX1A interaction could help treat ischemic stroke. In a cultured rat cortical neuronal model of chemical-induced, stroke-related neurotoxicity, a KCNB1-derived peptide...
BC Innovations | Jun 15, 2017
Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...
BC Innovations | May 9, 2017
Distillery Therapeutics


INDICATION: Huntington’s disease (HD) In vitro and mouse studies suggest an HIV tat -free, stapled BECN1 -derived peptide that inhibits autophagy could help treat HD and other neurodegenerative diseases. Chemical synthesis and testing in HeLa...
BC Innovations | Apr 27, 2017
Targets & Mechanisms

Selective senescence

A group at the Erasmus University Rotterdam has devised a strategy for inducing apoptosis only in senescent cells, and used it to create a cell-permeable peptide that it hopes to take to the clinic to...
Items per page:
1 - 10 of 53